新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 苏州生物纳米科技园 » 基石药业任命原默沙东全球肿瘤临床研发执行总监谢毅钊博士出任高级副总裁兼首席转化医学官

基石药业任命原默沙东全球肿瘤临床研发执行总监谢毅钊博士出任高级副总裁兼首席转化医学官

来源:Biobay 2018-12-02 11:22

近日,基石药业(苏州)有限公司宣布,任命谢毅钊博士为公司临床发展部高级副总裁兼首席转化医学官。谢博士拥有超过20年的全球肿瘤药物临床研发经验,他的加入将进一步加强公司管理团队的能力,加强基石药业在临床开发的核心优势,并巩固公司在中国创新生物制药公司中的领先地位。
基石药业专注于开发及商业化创新肿瘤免疫治疗及分子靶向药物。作为高级副总裁兼首席转化医学官,谢毅钊博士将负责药物从早期临床直至概念验证阶段(POC)的临床开发,并负责监管临床生物标记物的开发和应用,以支持公司肿瘤药管线的进一步拓展。谢博士对全球肿瘤领域的深入研究将有助公司进一步加强其在临床开发的核心优势,并巩固公司在中国创新生物制药公司中的领先地位。


谢毅钊博士
2018年5月,基石药业成功完成约2.62亿美元B轮融资,打破当时中国生物医药领域史上最大单笔B轮融资纪录。目前,基石药业肿瘤管线中已有8个候选药物处于临床阶段,包括4款处于或接近关键性试验阶段的候选药物。其中,公司自主开发的中国第一个全人源全长抗PD-L1单克隆抗体CS1001正处于III期临床试验阶段,有望成为中国上市的国内首批本土开发的PD-L1抗癌药物之一。2018年6月,基石药业先后与Blueprint Medicine和Agios达成独家合作和大中华区授权许可协议,引入四个完成临床概念验证阶段的产品,包括2018年7月获得美国FDA批准上市的ivosidenib,以及已进入全球III期临床试验,预计将于2019年上半年提交美国上市许可申请的avapritinib。
江宁军博士对此表示:“很高兴看到谢毅钊博士带着丰富的全球肿瘤研发经验加入我们,谢博士在衔接临床前和早期临床阶段的丰富经验,有助提高公司管线药物开发的整体成功率。作为基石药业的首席转化医学官,他的领导力、专业能力以及广泛的资源,对于公司实现在中国以及全球肿瘤领域开发创新药物的目标至关重要。”
加入基石药业之前,谢毅钊博士曾担任美国默克公司(在美国和加拿大之外称为默沙东)肿瘤早期临床研发部执行总监。在此之前,他曾担任日本第一三共制药公司肿瘤卓越策略团队负责人。谢博士在美国纪念斯隆-凯特琳癌症中心(MSKCC)接受肿瘤专科医师培训,并留任助理主治医师及研究员。期间,他在MSKCC附属的美国威尔·康乃尔医学院担任助理教授。
谢毅钊博士拥有美国南加州大学医学博士及生物化学与分子生物学博士学位。
谢毅钊博士表示:“基石药业建立强大丰富肿瘤药物管线的能力和临床开发方面的速度令人兴奋。我很荣幸加入这家潜力巨大的公司,并得以与经验丰富的管理团队合作,一起推动公司发展,让中国乃至全球的癌症患者受益。”

备注:以上公告中英文如有歧义,一律以英文版本为准。以下为英文版本。
Dr. Tse's Extensive Track Record in Oncology Early Clinical Development Will Strengthen CStone's Core Competence as a Clinical Development Engine and Solidify CStone's Position among Leading Innovative Biopharma Companies in China
SUZHOU, China, December 10, 2018 – CStone Pharmaceuticals, a biopharma company focused on developing and commercializing innovative immuno-oncology and molecularly targeted drugs, announced today the appointment of Archie Tse, M.D., Ph.D., as the newly established Senior Vice President, Chief Translational Medicine Officer (CTMO), reporting to Frank Jiang, M.D., Ph.D., Chairman and Chief Executive Officer. Dr. Tse has over 20 years of global oncology research and clinical development experience and will provide a strong addition to CStone’s senior leadership team.
In this role, Dr. Tse will be responsible for the development of assets at the early clinical development stage up to proof of concept (POC). He will oversee the development and implementation of clinical biomarkers to support progression of CStone’s pipelines. His in-depth understanding of the global oncology space will help further strengthen CStone’s core competence and solidify CStone’s position among leading innovative biopharma companies in China.  
In May 2018, CStone successfully completed a USD 262 million financing round, which was the largest Series B funding in the history of China biopharma industry at the time. Currently, CStone has eight clinical stage assets with four at or near registration trial. CS1001, China’s first fully human, full-length anti-PD-L1 monoclonal antibody developed by CStone, has initiated Phase III clinical studies, and will potentially become one of the first locally-developed anti-PD-L1 cancer drugs launched in China. In June 2018, CStone announced exclusive collaboration and license agreements with Blueprint Medicine and Agios. With these two deals, CStone in-licensed four post proof of concept assets, including ivosidenib, which received US FDA approval in July 2018, and avapritinib, which has entered global Phase III clinical studies and expects to file a US marketing application in H1 2019.
“We are thrilled to have Dr. Tse join the team and bring his profound global oncology research and clinical development experience,” said Frank Jiang, M.D., Ph.D., “Archie is highly experienced in bridging preclinical and early clinical phases to improve overall success of drug development. As CStone’s CTMO, his leadership, expertise and extensive network are critical in helping us advance toward our goal of developing innovative drugs in China and global oncology space.”    
Prior to joining CStone, Dr. Tse was the Executive Director of Global Oncology Early Development at Merck (known as MSD outside of US and Canada).  Before that, Dr. Tse served as the leader of the Oncology Team of Excellence for Strategy in Therapeutic Area at Daiichi-Sankyo. Dr. Tse is a board-certified medical oncologist trained at the US Memorial Sloan Kettering Cancer Center (MSKCC) where he stayed on to become a faculty as Assistant Physician and Assistant Member. In that period, he was also an Assistant Professor at the MSKCC affiliated Weill Cornell Medical School.
Dr. Tse obtained his M.D. and Ph.D. in Biochemistry & Molecular Biology from the University of Southern California, United States.
“I am very impressed by CStone’s remarkably rapid progress in the establishment and clinical development of its broad oncology portfolio,” Dr. Tse said. “It is a great honor for me to join this promising company and work with its seasoned management team to drive the Company’s growth for the benefit of cancer patients in China and worldwide.” 

关于基石药业/About CSTONE
基石药业为满足癌症患者需求而生,专注于开发及商业化创新肿瘤免疫治疗及分子靶向药物。成立2年多以来,公司已集结世界级的管理团队,在临床前研究、临床开发以及商业化方面拥有丰富经验。通过内部研发与外部合作组成的双重创新来源,公司已构建起拥有14种候选药物的强大抗肿瘤药管线,包括4个为Blueprint Medicine与Agios制药独家合作和授权产品,与自研管线一起具有单一及联合疗法的巨大潜力及协同效应。在研候选药物中,4款正处于或接近关键性试验阶段。基石药业的业务模式由临床研发驱动,并同时快速建立商业化及生产能力。公司目前受到知名投资者的支持,A轮与B轮融资额皆打破当时生物医药领域融资记录,两轮融资额共计4.12亿美元。在经验丰富的团队、具有潜力的研发管线、强大的业务模式和可持续的资金支持下,基石的愿景是通过为全球癌症患者带来创新差异化肿瘤疗法,成为全球知名的领先中国生物制药公司。
温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库